Thalia Therapeutics - CEO Interview
Summary
Our CEO, Dr David Solomon, recently spoke with BioHub about how Thalia Therapeutics is developing differentiated next-generation RNA therapeutics.
The interview also discusses our novel approach to cardiovascular disease, at a time when interest in genetically targeted therapies continues to grow, highlighted by recent research published in the New England Journal of Medicine.
Your question will be sent privately to Thalia Therapeutics. The company may choose to make this question public.
Start the conversation
Ask Thalia Therapeutics a question about this announcement.
Share your feedback
Discover